PRECISION RESEARCH MODELS INSIGHTS


Combination Immunotherapy Research with Syngeneic Tumor Models

In combination immunotherapy research, the goal is to coach multiple aspects of the body's own immune system to recognize and destroy cancerous cells. This strategy holds the promise of treating advanced tumors and keeping them at bay, with better responses and fewer side effects compared to more traditional chemotherapies. This has involved a paradigm shift in how scientists approach cancer research. For decades, the field has been...

Read More

Big Week for Immuno-Oncology Therapeutics

We've heard a lot about immune checkpoint inhibitor drugs in the news this week. Most notably, Merck & Co., Inc. (Merck) shared two major announcements involving their anti-PD-1 monoclonal antibody, Keytruda®. First, in a press release on October 21st, Merck announced the stoppage of a Phase III clinical trial for bladder cancer. Covering the announcement, BioSpace Online reported that "early results were so positive that the DMC...

Read More

Webinar: Humanized Mice in HIV Drug Discovery

Human immunodeficiency virus (HIV) and acquired immune deficient syndrome (AIDS) caused by HIV continue to impact approximately 36.7 million people worldwide. In the United States alone it is estimated that 50,000 new HIV infections occur each year, and that nearly one in eight HIV carriers are unaware of their status. Thanks to improvements in combined antiretroviral therapy (cART), HIV is no longer a death sentence. But despite...

Read More

What's in a Name? Origins of the CIEA NOG mouse®

The CIEA NOG mouse® is often referred to as an ideal mouse for engraftment of foreign (especially human) cells. The high rates of engraftment make NOG mice a preferred choice for patient-derived xenografts and humanized immune system mice studies. What special properties make the NOG mouse such a great acceptor of foreign cells and tissues? To answer this question, one need only look at the mouse line's...

Read More

Guidelines for Use of Humanized Mice in IBD Drug Discovery

Inflammatory Bowel Disease (IBD) is a chronic immunologically mediated disease with no known cure. Can humanized mice speed up IBD drug discovery, bringing relief to the estimated 1.4 million Americans with this difficult condition? To support IBD research, Taconic hosted a webinar by TransCure BioServices experts: Chief Executive Officer (CEO), Dr. Patrick Nef, and Chief Scientific Officer (CSO), Dr. Sebastien Tabruyn. TransCure is a contract research organization...

Read More

Are Humanized Mice the Future of Oncology Models?

Oncologists are up against the limits of cell cultures and xenografts in applied research. Are humanized mice the solution? In an article discussing the challenge of tumor heterogeneity, Drug Discovery News (DDN) laid out several factors which contribute to heterogeneity and which complicate the clinical presentation of tumors, but which are not well modeled in cell culture: Genetically diverse subclonal populations, both within a tumor and across...

Read More

Preclinical Immuno-Oncology Animal Models

Immuno-oncology - triggering a patient's own immune system to attack their cancer - is sweeping through all levels of oncology research, from academia to biotech and pharma. Silicon Valley mogul Sean Parker, co-founder of Napster and first president of Facebook, pledged $250 million to set up the Parker Institute for Cancer Immunotherapy. Pharma and biotech are betting big on immunotherapy also, with significant resources devoted to immunotherapy...

Read More

Patient-derived Xenografts of Hematological Malignancies Webinar Review

Dr. Julia Schueler of Oncotest presented a webinar exploring her work with patient-derived xenografts (PDX) of hematological malignancies as model systems for drug development and tumor biology research. PDX models of hematological origin provide the same advantages as solid tumor PDX models, such as preserving tumor heterogeneity and the treatment sensitivity profile of the donor patient. View the webinar: Patient-Derived Xenografts of Hematological Malignancies For successful development...

Read More

Review: Humanized Mouse Model Research Symposia

Humanized mouse models are critical tools for basic research, modeling of certain human-specific infectious diseases, efficacy testing of immunotherapy approaches, and safety assessment for large molecule therapeutics. Taconic Biosciences recently hosted the symposium series "Advanced Preclinical Models for Immuno-oncology and Infectious Disease" in several European cities, which focused on the latest research applications of human immune system engrafted mice and the introduction of next generation models. International...

Read More

Patient-Derived Xenografts Q&A with Dr. Els Hermans

Dr. Els Hermans, whose work on the Trace platform at KU Leuven is streamlining the oncology R&D pipeline, presented a webinar focused on the application of patient-derived xenograft models (PDX) in translational cancer research. Her presentation on use of PDX models to close the gap between pre-clinical and clinical trials, and their application in personalized medicine, generated substantial interest from the research community. View the webinar: Patient-Derived...

Read More